- Pharmaceutical giant Novo Nordisk announced substantial reductions in the list prices of its popular GLP-1 medications, Wegovy and Ozempic, with Wegovy seeing a 50% cut and Ozempic a 35% reduction.
- According to CBS News, these new prices, set at $675 per month for each drug, will take effect starting January 1, 2027.
- This strategic move aims to improve patient access and affordability, particularly for millions in the United States living with obesity and type 2 diabetes.
- The company stated that this action directly responds to calls from private and public payers, as well as patients, to lower cost barriers, as reported by Fierce Pharma.
- The price decrease is primarily intended to benefit individuals whose out-of-pocket costs are linked to the list price, such as those with high-deductible health plans or co-insurance arrangements.
- As noted in a PR Newswire release, these changes in list price will not impact direct-to-patient, self-pay prices for the medications.
Novo Nordisk Cuts GLP-1 Drug Prices
Pharmaceutical giant Novo Nordisk announced significant price reductions for its popular GLP-1 medications, Wegovy and Ozempic, slashing their list prices by 50% and 35% respectively. Effective January 1, 2027, both drugs will cost $675 per month, a strategic move aimed at improving patient access and affordability, particularly for those with high-deductible health plans.
Sources
6
Editorial Process: This article was drafted using AI-assisted research and thoroughly reviewed by human editors for accuracy, tone, and clarity. All content undergoes human editorial review to ensure accuracy and neutrality.
Reviewed by: Pat Chen
Report an issue with this article
Please sign in to report issues with this article.
Live discussion about this article
Comments
Comments are disabled for this article.
